Krebs Biochemicals

Hyderabad, India Founded: 1991 • Age: 35 yrs Listed
Biotech processes are developed for medicine and agriculture uses.

About Krebs Biochemicals

Krebs Biochemicals is a publicly listed company based in Hyderabad (India) founded in 1991. Biotech processes are developed for medicine and agriculture uses. The company has 28 employees. Its Indian entity Krebs Biochemicals And Industries Limited reported revenue of β‚Ή25.76 Cr. Krebs Biochemicals offers products and services including Biotech Processes. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.

Company details

Founded in 1991 and based in Hyderabad, India, Krebs Biochemicals operates in the biopharma sector. Commercially viable biotech processes are developed for applications in medicine and agriculture. Current manufacturing includes Androstenedione as a steroid intermediate, along with Lovastatin and Simvastatin for anti-cholesterol treatments. Products under development encompass amlodipine and Telmisartan for anti-hypertension, Cetirizine for anti-histamine effects, Orlistat for anti-obesity, Serratiopeptidase for anti-inflammatory purposes, and Phenylephrine for cold and cough relief.

  • Headquarters Hyderabad, India
  • Employees 28
  • Stage Public
  • Sectors
    Healthcare
  • Website krebsbiochem.com
  • Social LinkedIn
  • Legal Name Krebs Biochemicals & Industries Ltd.
Key Metrics
  • Market Cap
    ₹127 Cr

    KREBSBIO · NSE

  • Share Price
    ₹57.15

    -3.12% today

  • Revenue
    ₹23.73 Cr

    FY 2025-26 · -45.2% YoY

  • EBITDA
    −₹5.45 Cr

    Margin -23.0%

  • Net Profit
    −₹16.93 Cr

    FY 2025-26 · +37.4% YoY

  • Employee Count
    28

Products & Services of Krebs Biochemicals

Krebs Biochemicals offers a comprehensive portfolio of products and services, including Biotech Processes.

Biotech Processes
Manufacturing Services

Develops processes for medicine and agriculture applications

Board of directors of Krebs Biochemicals And Industries Limited (Krebs Biochemicals)

Krebs Biochemicals And Industries Limited is the primary company behind Krebs Biochemicals. The board of Krebs Biochemicals And Industries Limited currently have 8 directors; the longest-serving is Ravi Ravindranath Tagore, appointed in 1992. 27 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ravi Ravindranath Tagore
DIN 00272977
Director12 Oct 199234 yrs 1 moKrebs Biochemicals And Industries Limited
Avinash Ravi
DIN 01616152
Director13 Aug 201511 yrs 3 moKrebs Biochemicals And Industries Limited
Pabitrakumar Kalipada Bhattacharyya
DIN 07131152
Director10 Aug 20233 yrs 3 moKrebs Biochemicals And Industries Limited
Popatlal Mukanchand Kathariya
DIN 00281395
Director04 Feb 20251 yr 9 moKrebs Biochemicals And Industries Limited
Dipti Chinubhai Shah
DIN 07995542
Director04 Feb 20251 yr 9 moKrebs Biochemicals And Industries Limited
Satya Prakash Chigurupati
DIN 00721318
Director04 Feb 20251 yr 9 moKrebs Biochemicals And Industries Limited
Sumanth Karlapudi
DIN 09188185
Director04 Feb 20251 yr 9 moKrebs Biochemicals And Industries Limited
Manish Kumar Jain
DIN 06477976
Managing Director07 Aug 20251 yr 3 moKrebs Biochemicals And Industries Limited

IPO & Listings of Krebs Biochemicals

Krebs Biochemicals is a publicly listed company on the NSE with ticker symbol KREBSBIO in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date17 May 2000
  • Listed onBSE: 524518
  • Listed entityKrebs Biochemicals & Industries Ltd.
  • Exchange sectorHealth technology
  • ISININE268B01013
  • Share price₹60.41 (+5.45% on the day) · 2026-10-14
  • Market capitalisation₹122 Cr
  • EPS (diluted, trailing year)₹-6.54
  • Volume (last session)47,475

Financials of Krebs Biochemicals

Exchange-reported figures of Krebs Biochemicals And Industries Limited, the listed company behind Krebs Biochemicals (NSE: KREBSBIO).

Financial Highlights

FY 2025-26 Β· Standalone
Revenue
₹23.73 Cr
-45.2% YoY
EBITDA
−₹5.45 Cr
+63.7% YoY
Profit After Tax
−₹16.93 Cr
+37.4% YoY
Net Worth
−₹32.76 Cr
-101.7% YoY
Total Assets
₹111 Cr
-4.3% YoY
Total Debt
₹94.84 Cr
+15.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue23.7343.3150.4252.1359.7053.7033.41
Revenue growth-45.2%-14.1%-3.3%-12.7%+11.2%+60.7%-
EBITDA(5.45)(15.03)(8.71)(15.80)(33.99)(17.56)(18.56)
EBITDA margin-23.0%-34.7%-17.3%-30.3%-56.9%-32.7%-55.6%
Profit before tax(16.93)(26.92)(19.72)(24.71)(44.52)(28.34)(28.87)
Net profit(16.93)(27.06)(19.72)(24.71)(44.52)(28.34)(28.88)
Net profit margin-71.3%-62.5%-39.1%-47.4%-74.6%-52.8%-86.4%
EPS (β‚Ή)(7.85)(12.49)(9.15)(11.45)(20.65)(14.45)(16.04)
Balance sheet
Total assets11111612713612212291.37
Net worth(32.76)(16.24)10.7830.5454.91(12.73)5.00
Total debt94.8482.2163.6853.3713.1081.1436.22
Cash & bank0.130.140.140.090.100.710.17
Net working capital(42.16)(42.31)(34.21)(22.91)(32.41)(16.18)(23.57)
Cash flow
Cash from operations(1.92)(7.89)2.36(24.71)(17.22)(14.57)(35.50)
Cash from investing(3.64)(4.97)(7.82)(12.65)(22.90)(22.55)(10.22)
Cash from financing5.5412.865.5037.3439.5137.6628.58
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue5.796.986.817.274.175.486.1011.47
Revenue growth (YoY)+38.9%+27.4%+11.6%-36.6%-67.6%-57.5%--
Other income0.040.162.000.000.010.010.340.25
Total expenses7.726.167.686.986.967.5711.5116.18
EBITDA(1.93)0.82(0.87)0.29(2.79)(2.09)(5.41)(4.71)
EBITDA margin-33.3%+11.7%-12.8%+4.0%-66.9%-38.1%-88.7%-41.1%
Depreciation1.611.591.571.631.621.601.571.72
Interest1.901.881.911.791.731.651.611.56
Profit before tax(5.40)(2.49)(2.35)(3.13)(6.13)(5.33)(8.25)(7.74)
Tax0.000.000.000.000.000.000.020.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 19 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue5.796.986.817.274.175.486.1011.47
Revenue growth (YoY)+38.9%+27.4%+11.6%-36.6%-67.6%-57.5%--
Other income0.040.162.000.000.010.010.340.25
Total expenses7.726.167.686.986.967.5711.5116.18
EBITDA(1.93)0.82(0.87)0.29(2.79)(2.09)(5.41)(4.71)
EBITDA margin-33.3%+11.7%-12.8%+4.0%-66.9%-38.1%-88.7%-41.1%
Depreciation1.611.591.571.631.621.601.571.72
Interest1.901.881.911.791.731.651.611.56
Profit before tax(5.40)(2.49)(2.35)(3.13)(6.13)(5.33)(8.25)(7.74)
Tax0.000.000.000.000.000.000.020.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue23.7343.3150.4252.1359.7053.7033.41
Revenue growth-45.2%-14.1%-3.3%-12.7%+11.2%+60.7%-
Other income2.030.710.450.621.160.620.37
Total expenses29.1858.3459.1367.9393.6971.2651.97
Employee cost0.0016.3016.1715.5414.9615.3014.56
EBITDA(5.45)(15.03)(8.71)(15.80)(33.99)(17.56)(18.56)
EBITDA margin-23.0%-34.7%-17.3%-30.3%-56.9%-32.7%-55.6%
Depreciation6.426.696.776.566.305.124.68
Interest7.095.914.692.975.396.286.00
Profit before tax(16.93)(26.92)(19.72)(24.71)(44.52)(28.34)(28.87)
Tax0.000.020.000.000.000.000.00
Net profit(16.93)(27.06)(19.72)(24.71)(44.52)(28.34)(28.88)
Net profit margin-71.3%-62.5%-39.1%-47.4%-74.6%-52.8%-86.4%
EPS (β‚Ή)(7.85)(12.49)(9.15)(11.45)(20.65)(14.45)(16.04)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital15215215215215249.6248.00
Reserves & surplus(184)(168)(141)(121)(96.65)(66.52)(43.00)
Shareholders' funds (net worth)(32.76)(16.24)10.7830.5454.91(12.73)5.00
Secured loans0.000.000.000.000.0071.1435.51
Unsecured loans94.8482.2163.6853.3713.1010.000.71
Total debt94.8482.2163.6853.3713.1081.1436.22
Total liabilities11111612713612212291.37
Assets
Gross block314314312303288261243
Net block142146150147139118105
Capital work in progress1.593.092.004.098.3811.944.19
Investments0.000.000.000.000.000.000.00
Inventories5.706.039.8011.9525.5616.6015.00
Sundry debtors0.000.051.900.530.880.300.20
Cash & bank balances0.130.140.140.090.100.710.17
Loans & advances3.794.045.613.508.953.813.49
Total current assets9.6210.2617.4516.0735.4921.4218.86
Total current liabilities51.7852.5751.6638.9867.9037.6042.43
Net working capital(42.16)(42.31)(34.21)(22.91)(32.41)(16.18)(23.57)
Total assets11111612713612212291.37
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.140.140.090.100.710.1717.32
Net cash from operating activities(1.92)(7.89)2.36(24.71)(17.22)(14.57)(35.50)
Net cash from investing activities(3.64)(4.97)(7.82)(12.65)(22.90)(22.55)(10.22)
Net cash from financing activities5.5412.865.5037.3439.5137.6628.58
Net change in cash(0.01)0.000.05(0.01)(0.61)0.54(17.14)
Closing cash0.130.140.140.090.100.710.17
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-45.2%-14.1%-3.3%-12.7%+11.2%+60.7%-
EBITDA growth+63.7%-72.6%+44.9%+53.5%-93.6%+5.4%-
PBT growth+37.1%-36.5%+20.2%+44.5%-57.1%+1.8%-44.4%
Net income growth+37.4%-37.2%+20.2%+44.5%-57.1%+1.9%-
Revenue CAGR (3Y)-23.1%-10.2%-2.1%+16.0%+7.7%+16.7%+117.2%
EBITDA CAGR (3Y)-29.8%-23.8%-20.8%-5.2%+51.6%+25.6%+28.6%
Profitability & leverage
Net income margin-71.4%-62.2%-39.1%-47.4%-74.6%-52.8%-86.4%
Return on capital employed0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Return on net worth0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Debt / equity0.000.002.830.782.230.000.00
Long-term debt / equity0.000.002.340.541.740.000.00
Interest cover-59.68-27.21-30.30-13.28-13.38-27.69-25.82
Efficiency & per share
Fixed asset turnover0.080.140.160.180.220.210.14
Inventory turnover4.055.474.642.782.833.402.79
Debtors turnover949.2044.4241.5073.94101.19214.8021.49
EPS (β‚Ή)(7.85)(12.49)(9.15)(11.45)(20.65)(14.45)(16.04)
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)(75.49)(67.83)(55.29)(46.13)(34.83)(23.91)(13.89)

Similar companies to Krebs Biochemicals

Krebs Biochemicals has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
lauruslabs.com2005Hyderabad, India$229.73M6,035
Pharmaceutical and biotechnology company
symbiotec.in2002Indore, India$61.01M1,822
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
sequent.in2002Bengaluru, India
APIs are developed and manufactured for therapeutic areas.
Premium access

Detailed similar companies of Krebs Biochemicals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Krebs Biochemicals

The website of Krebs Biochemicals (krebsbiochem.com) receives about 1.1K visits a month.

  • Monthly visits
    1.1K

    ▲ 28.5% vs previous month

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Krebs Biochemicals (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Krebs Biochemicals

Premium access

Complete news archive for Krebs Biochemicals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Krebs Biochemicals

Krebs Biochemicals was founded in 1991.

Krebs Biochemicals is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Krebs Biochemicals has 28 employees.

The primary company behind Krebs Biochemicals, Krebs Biochemicals And Industries Limited, reported revenue of β‚Ή25.76 Cr for FY 2026, down 45% year on year.

Founded in 1991 and based in Hyderabad, India, Krebs Biochemicals operates in the biopharma sector. Commercially viable biotech processes are developed for applications in medicine and agriculture. Current manufacturing includes Androstenedione as a steroid intermediate, along with Lovastatin and Simvastatin for anti-cholesterol treatments. Products under development encompass amlodipine and Telmisartan for anti-hypertension, Cetirizine for anti-histamine effects, Orlistat for anti-obesity, Serratiopeptidase for anti-inflammatory purposes, and Phenylephrine for cold and cough relief.

Krebs Biochemicals's top competitors include Laurus Labs, Symbiotec and SeQuent.

Krebs Biochemicals offers Biotech Processes.

Yes, Krebs Biochemicals is publicly traded on NSE under the ticker symbol KREBSBIO.

Krebs Biochemicals operates through Krebs Biochemicals And Industries Limited.

The legal entities of Krebs Biochemicals currently have 10 directors, including Avinash Ravi, Ravi Ravindranath Tagore, Pabitrakumar Kalipada Bhattacharyya and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available